Expression of basic fibroblast growth factor, vascular endothelial growth factor, and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas

被引:16
作者
Oh, CK
Kwon, YW
Kim, YS
Jang, HS
Kwon, KS
机构
[1] Pusan Natl Univ, Coll Med, Dept Dermatol, Seo Ku, Pusan 602739, South Korea
[2] NIAID, Mol Pathol Sect, Immunopathol Lab, NIH, Rockville, MD 20852 USA
[3] Pusan Natl Univ, Inst Med Res, Pusan, South Korea
关键词
basal cell carcinoma; bFGF; VEGF; TSP-1; microvessel density;
D O I
10.1111/j.1346-8138.2003.tb00392.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The aggressive forms of basal cell carcinoma (BCC) are biologically different in a number of features from their nonaggressive counterparts. The expression of basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF), and Thrombospondin-1 (TSP-1) was examined in primary culture samples of nonaggressive and aggressive BCCs. We studied the relationship between neoangiogenesis by counting microvessels, tumor aggressiveness, and the expression of three different angiogenic factors. bFGF mRNA was detectable in all BCC samples, but there was no significant difference in the levels of expression between the two types. VEGF mRNA was also detectable in all BCC samples. VEGF expression in the aggressive type was approximately 3.5-fold higher than in the nonaggressive type. TSP-1 expression was variable and not related to the type of BCC. The mean value of microvessel density (MVD) was significantly higher for the aggressive type than for the nonaggressive type. There was a significant correlation between VEGF levels and MVD. No significant relationships were found between bFGF, TSP-1 mRNA expression, and MVD. In conclusion, the results of present study suggest that VEGF expression and angiogenesis might play important roles in the progression to aggressive BCC.
引用
收藏
页码:306 / 313
页数:8
相关论文
共 24 条
[1]   KERATINOCYTE EXPRESSION OF CD36 ANTIGEN IN BENIGN AND MALIGNANT EPIDERMAL CELL-DERIVED TUMORS [J].
ALLEN, MH ;
BARKER, JNWN ;
MACDONALD, DM .
JOURNAL OF CUTANEOUS PATHOLOGY, 1991, 18 (03) :198-203
[2]   THE FGF FAMILY OF GROWTH-FACTORS AND ONCOGENES [J].
BASILICO, C ;
MOSCATELLI, D .
ADVANCES IN CANCER RESEARCH, 1992, 59 :115-165
[3]   Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization [J].
Bleuel, K ;
Popp, S ;
Fusenig, NE ;
Stanbridge, EJ ;
Boukamp, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) :2065-2070
[4]   MICROVESSEL QUANTITATION AND PROGNOSIS IN INVASIVE BREAST-CARCINOMA [J].
BOSARI, S ;
LEE, AKC ;
DELELLIS, RA ;
WILEY, BD ;
HEATLEY, GJ ;
SILVERMAN, ML .
HUMAN PATHOLOGY, 1992, 23 (07) :755-761
[5]   CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells [J].
Dawson, DW ;
Pearce, SFA ;
Zhong, RQ ;
Silverstein, RL ;
Frazier, WA ;
Bouck, NP .
JOURNAL OF CELL BIOLOGY, 1997, 138 (03) :707-717
[6]  
GRAHAM CH, 1994, AM J PATHOL, V145, P510
[7]   Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].
Hanahan, D ;
Folkman, J .
CELL, 1996, 86 (03) :353-364
[8]   MATRIX METALLOPROTEINASES IN BLOOD-VESSEL DEVELOPMENT IN HUMAN FETAL SKIN AND IN CUTANEOUS TUMORS [J].
KARELINA, TV ;
GOLDBERG, GI ;
EISEN, AZ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 105 (03) :411-417
[9]  
Lupetti R, 1996, INT J CANCER, V66, P110, DOI 10.1002/(SICI)1097-0215(19960328)66:1<110::AID-IJC19>3.3.CO
[10]  
2-5